CD4+ T-cell clones recognizing human lymphoma-associated antigens: Generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells

Blood

Volumn 114, Issue 4, 2009, Pages 807-815

  Long, Heather M ^a   Zuo, Jianmin ^a   Leese, Alison M ^a   Gudgeon, Nancy H ^a   Jia, Hui ^a   Taylor, Graham S ^a   Rickinson, Alan B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; TUMOR ANTIGEN;

ALLELE; ARTICLE; B LYMPHOBLAST; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CLONING; CELL STIMULATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; EPSTEIN BARR VIRUS; GENOME; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; CELL CLONE; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CULTURE TECHNIQUE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; VIRUS CELL TRANSFORMATION;

ANTIGENS, CD95; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA;

EID: 68249134201     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-194043     Document Type: Article

References (50)

1. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175-208.
2. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother. 2005;54:187-207. (Pubitemid 32250041)
3. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617. (Pubitemid 46697918)
4. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29-44.
5. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields B, et al, eds. Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:2655-2700.
6. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A. 1999;96:10391-10396. (Pubitemid 29422568)
7. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.
8. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92: 1549-1555.
9. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360:436-442. (Pubitemid 34880139)
10. Gottschalk S, Ng CY, Perez M, et al. An Epstein- Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001;97: 835-843. (Pubitemid 32154261)
11. Sherritt MA, Bharadwaj M, Burrows JM, et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation. 2003; 75:1556-1560. (Pubitemid 36597295)
12. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555. (Pubitemid 26150682)
13. Wilkie GM, Taylor C, Jones MM, et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J Immunother. 2004; 27:309-316. (Pubitemid 38833327)
14. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99:2592-2598. (Pubitemid 34525450)
15. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive post-transplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123-1131. (Pubitemid 47281407)
16. Rowe M, Khanna R, Jacob CA, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol. 1995;25:1374-1384.
17. Khanna R, Burrows SR, Argaet V, Moss DJ. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol. 1994;6:639-645. (Pubitemid 24111615)
18. Paludan C, Bickham K, Nikiforow S, et al. Epstein- Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol. 2002;169:1593-1603. (Pubitemid 34809208)
19. Khanna R, Burrows SR, Thomson SA, et al. Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J Immunol. 1997; 158:3619-3625. (Pubitemid 127488714)
20. Gudgeon NH, Taylor GS, Long HM, Haigh TA, Rickinson AB. Regression of Epstein-Barr virusinduced B-cell transformation in vitro involves virus- specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. J Virol. 2005;79:5477-5488.
21. Adhikary D, Behrends U, Boerschmann H, et al. Immunodominance of lytic cycle antigens in Epstein- Barr virus-specific CD4+ T cell preparations for therapy. PLoS ONE. 2007;2:e583. (Pubitemid 351266394)
22. Long HM, Haigh TA, Gudgeon NH, et al. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent- cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol. 2005;79:4896-4907.
23. Mautner J, Pich D, Nimmerjahn F, et al. Epstein- Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. Eur J Immunol. 2004;34:2500-2509. (Pubitemid 39302807)
24. Feederle R, Kost M, Baumann M, et al. The Epstein- Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 2000;19:3080-3089. (Pubitemid 30386778)
25. Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science. 1991;251:70-72. (Pubitemid 21916853)
26. Leen A, Meij P, Redchenko I, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001;75:8649-8659. (Pubitemid 32768969)
27. Hislop AD, Gudgeon NH, Callan MF, et al. EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol. 2001;167: 2019-2029.
28. Taylor GS, Long HM, Haigh TA, Larsen M, Brooks J, Rickinson AB. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol. 2006;177:3746-3756. (Pubitemid 44359907)
29. Rooney CM, Rickinson AB, Moss DJ, Lenoir GM, Epstein MA. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int J Cancer. 1984;34:339-348.
30. Kataoka T, Shinohara N, Takayama H, et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol. 1996;156:3678-3686. (Pubitemid 26139940)
31. Wallace LE, Rickinson AB, Rowe M, Moss DJ, Allen DJ, Epstein MA. Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line, I: virusspecific and nonspecific components of the cytotoxic response. Cell Immunol. 1982;67:129-140. (Pubitemid 12189635)
32. Metes D, Storkus W, Zeevi A, et al. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. Transplantation. 2000;70:1507-1515. (Pubitemid 30954079)
33. Bhaduri-McIntosh S, Rotenberg MJ, Gardner B, Robert M, Miller G. Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines. Blood. 2008;111:1334-1343. (Pubitemid 351213420)
34. Pudney VA, Leese AM, Rickinson AB, Hislop AD. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med. 2005;201:349-360.
35. Savoldo B, Cubbage ML, Durett AG, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002; 168:909-918. (Pubitemid 34049595)
36. Moretta A, Comoli P, Montagna D, et al. High frequency of Epstein-Barr virus (EBV) lymphoblastoid cell line-reactive lymphocytes in cord blood: evaluation of cytolytic activity and IL-2 production. Clin Exp Immunol. 1997;107:312-320. (Pubitemid 27049258)
37. Wilson AD, Morgan AJ. Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro. J Virol. 2002;76:5071-5081.
38. Misko IS, Sculley TB, Schmidt C, Moss DJ, Soszynski T, Burman K. Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component. Cell Immunol. 1991; 132:295-307.
39. Honda S, Takasaki T, Okuno K, Yasutomi M, Kurane I. Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones. Acta Virol. 1998;42:307-313. (Pubitemid 29110610)
40. Khanolkar A, Yagita H, Cannon MJ. Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells. Virology. 2001;287:79-88. (Pubitemid 32778241)
41. Misko IS, Pope JH, Hutter R, Soszynski TD, Kane RG. HLA-DR-antigen- associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer. 1984;33:239-243. (Pubitemid 14184413)
42. Sun Q, Burton RL, Lucas KG. Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood. 2002;99:3302-3309. (Pubitemid 34525311)
43. Wilson AD, Hopkins JC, Morgan AJ. In vitro cytokine production and growth inhibition of lymphoblastoid cell lines by CD4+ T cells from Epstein- Barr virus (EBV) seropositive donors. Clin Exp Immunol. 2001;126:101-110.
44. Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein- Barr virus-transformed B cells. Int J Cancer. 1994;58:69-79. (Pubitemid 24213972)
45. Perez SA, Sotiropoulou PA, Sotiriadou NN, et al. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones. Cancer Immunol Immunother. 2002;50:615-624.
46. Mi JQ, Manches O, Wang J, et al. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma. Br J Haematol. 2006;135:324-335. (Pubitemid 44488535)
47. Wilson AD, Redchenko I, Williams NA, Morgan AJ. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis. Int Immunol. 1998;10: 1149-1157. (Pubitemid 28362689)
48. Ochoa MT, Stenger S, Sieling PA, et al. T-cell release of granulysin contributes to host defense in leprosy. Nat Med. 2001;7:174-179. (Pubitemid 32148483)
49. Zhang Y, Chaux P, Stroobant V, et al. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol. 2003; 171:219-225. (Pubitemid 36745291)
50. Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003;110:139-148. (Pubitemid 37340192)